Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00897494 · ClinicalTrials.gov registry record
Identification of Biomarkers for Early Detection of Pancreatic Cancer
A clinical trial, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- 75
- Enrollment target
NCT00897494 is a clinical trial that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 75 participants.
The verdict
NCT00897494 has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that may help in the early detection of pancreatic cancer.
Interventions
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- OTHER mass spectrometry
- OTHER surface-enhanced laser desorption/ionization-time of flight mass spectrometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-02 |
| Est. Completion | 2011-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00897494
The ClinicalTrials.gov registry entry for NCT00897494 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which protein expression analysis is the first listed.
NCT00897494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00897494 about?
NCT00897494 is a clinical study titled "Identification of Biomarkers for Early Detection of Pancreatic Cancer". RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that...
What is the current status of trial NCT00897494?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2005-02. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00897494?
The interventions under investigation include: protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), mass spectrometry (OTHER), surface-enhanced laser desorption/ionization-time of flight mass spectrometry (OTHER).
Who is sponsoring clinical trial NCT00897494?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.